Antiretroviral drug resistance among antiretroviral‐naïve and treatment experienced patients infected with HIV in Iran. Issue 7 (17th April 2014)

• Record Type: Journal Article
• Authors: Baesi, Kazem; Ravanshad, Mehrdad; Ghanbarisafari, Maryam; Saberfar, Esmaeil; SeyedAlinaghi, SeyedAhmad; Volk, Jonathan E.
• Is Part Of: Journal of medical virology. Volume 86:Issue 7(2014:Jul.)
• Page Start: 1093
• Page End: 1098
• Publication Date: 2014-04-17
• Subjects: Virology -- Periodicals; 616
• DOI: 10.1002/jmv.23898
• Languages: English
• ISSNs: 0146-6615

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="jmv23898-sec-0001" sec-type="section"> <p>Resistance to antiretroviral therapy (ART) threatens the success of programs to reduce HIV morbidity and mortality, particularly in countries with few treatment options. In the present study, genotype and phenotype data from ART‐naïve and experienced hospitalized patients infected with HIV in Tehran, Iran were used to assess the prevalence and types of transmitted (TDR) and acquired drug resistance (ADR) mutations. All 30 participants naïve to ART and 62 of 70 (88.6%) participants receiving ART had detectable viral loads. Among participants receiving ART with sequencing data available (n = 62), 36 (58.1%) had at least one drug resistance mutation; the most common mutations were K103N (21.0%), M184V (19.4%), and the thymidine analogue mutations. Seven (11.3%), 27 (43.5%), and two (3.2%) of these participants had resistance to one, two, and three drug classes, respectively. High‐level resistance to efavirenz (EFV) was more common among participants on EFV‐based regimens than high‐level lopinavir/ritonivar (LPV/r) resistance among those on LPV/r‐based regimens (55.3% vs. 6.7%, <italic>P</italic> < 0.0001). Two (6.7%) antiretroviral‐naïve participants had K103N mutations. These findings document an alarmingly high frequency of multiple HIV drug class resistance in Iran, confirm the presence of TDR, and highlight the need for systematic viral load monitoring and drug resistance testing, including at diagnosis. Expanded access to new antiretroviral medications from additional drug classes is needed. <bold><italic>J. Med. Virol. 86:1093–1098, 2014</italic>.</bold> © 2014 Wiley Periodicals, Inc.</p> </sec> </abstract>